TG Therapeutics Inc
$ 49.52
3.06%
12 Jun - close price
- Market Cap 7,355,666,000 USD
- Current Price $ 49.52
- High / Low $ 50.41 / 47.96
- Stock P/E 16.80
- Book Value 4.11
- EPS 2.86
- Next Earning Report 2026-08-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 1.13 %
- 52 Week High 50.39
- 52 Week Low 25.28
About
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Analyst Target Price
$48.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-26 | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-03-03 | 2024-11-04 | 2024-08-06 | 2024-05-01 | 2024-02-28 | 2023-11-01 | 2023-08-01 |
| Reported EPS | 0.18 | 0.14 | 0.16 | 0.17 | 0.03 | 0.15 | 0.02 | 0.04 | -0.07 | -0.1 | 0.73 | -0.34 |
| Estimated EPS | 0.28 | 0.3271 | 0.22 | 0.29 | 0.17 | 0.09 | 0.03 | -0.04 | -0.04 | -0.1 | 0.1 | -0.25 |
| Surprise | -0.1 | -0.1871 | -0.06 | -0.12 | -0.14 | 0.06 | -0.01 | 0.08 | -0.03 | 0 | 0.63 | -0.09 |
| Surprise Percentage | -35.7143% | -57.1996% | -27.2727% | -41.3793% | -82.3529% | 66.6667% | -33.3333% | 200% | -75% | 0% | 630% | -36% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TGTX
2026-06-12 20:39:22
At TG Therapeutics' 2026 Annual Meeting, shareholders rejected the advisory vote on executive compensation, with 48,858,169 votes against and 31,905,837 for. While directors were re-elected and KPMG LLP was ratified as the independent auditor, the "say-on-pay" outcome signals significant shareholder dissatisfaction with executive compensation. This non-binding vote is expected to prompt the board to review pay structures and engage with shareholders.
2026-06-12 15:39:22
TG Therapeutics (TGTX) saw its shares rise after announcing positive topline results from its Phase 1 study of subcutaneous Briumvi (ublituximab) for the treatment of Myasthenia Gravis (MG). The study met its primary endpoint, demonstrating that the subcutaneous formulation achieved comparable exposure and bioequivalence to the intravenous formulation at 24 hours post-dose. These results support the potential for a more convenient subcutaneous self-administration option for patients with MG.
2026-06-12 04:38:50
TG Therapeutics (TGTX) reported positive Phase 1 data for a high-concentration subcutaneous formulation of BRIUMVI for relapsing multiple sclerosis, showing comparable pharmacokinetic, pharmacodynamic, safety, and tolerability results to the approved intravenous version. This development supports ongoing Phase 3 trials and suggests potential for at-home administration via an autoinjector. The news bolsters the investment narrative for TG Therapeutics, particularly ahead of the subcutaneous BRIUMVI Phase 3 readout expected in late 2026 or early 2027.
2026-06-10 17:40:39
TG Therapeutics (TGTX) stock has surged over 8.58% following positive clinical trial data for its anti-CD20 therapy, Briumvi. Key catalysts include Phase 3 ENHANCE data showing bioequivalence with a simpler single-dose regimen, strong Phase 1 subcutaneous Briumvi data supporting at-home administration, and positive early results in myasthenia gravis, expanding its potential market. The company reports strong financials with significant revenue, high margins, and profitability, making it an attractive prospect for momentum traders despite the inherent volatility of biotech stocks.
2026-06-10 14:40:39
TG Therapeutics (TGTX) stock has reached a new 52-week high of $44.70, currently trading at $45.16. The stock has seen significant year-to-date and six-month gains of 45% and 42% respectively, with InvestingPro analysis suggesting it is undervalued. Despite strong market performance, the company recently reported a Q1 2026 EPS miss and slightly lower-than-expected revenue, though it has announced positive clinical trial updates for its drug BRIUMVI.
2026-06-10 05:39:45
TG Therapeutics (TGTX) is gaining attention due to positive clinical data and formulation updates for its drug BRIUMVI, leading to a significant increase in its share price. Despite recent gains, the stock is considered slightly undervalued by analysts, with a key future growth driver being the planned launch of a subcutaneous BRIUMVI formulation. Investors are encouraged to review the company's detailed analysis to understand the valuation and potential risks.
